NasdaqGM:ORKABiotechs
Board Refresh at Oruka Therapeutics (ORKA): Does a Commercial Veteran Signal a Shift Toward Launch Readiness?
In December 2025, Oruka Therapeutics announced that Board member Cameron Turtle resigned and was replaced by commercial veteran Chris Martin, who will serve as a Class II director and chair the Compensation Committee while also joining the Audit Committee.
Martin’s track record in building and executing launch strategies at companies that later attracted multi-billion-dollar acquisitions highlights Oruka’s increasing focus on preparing its pipeline for potential commercialization.
We’ll now...